MAPT and Alzheimer disease: The biomarkers amyloid-beta (Aβ) and tau in cerebrospinal fluid (CSF) or amyloid and tau load via positron emission tomography (PET) have become indispensable in the AD research field, especially as part of clinical trials for disease modification and secondary prevention [3–6].